Coca-Cola (KO) Q3 2025 earnings


Sina Schuldt | Picture Alliance | Getty Images

Coca-cola reported quarterly earnings and revenue that topped expectations, but the beverage giant said that demand for its drinks is still soft.

Here’s what the company reported compared with what Wall Street analysts surveyed by LSEG were expecting:

  • Earnings per share: 82 cents adjusted vs. 78 cents expected
  • Revenue: $12.41 billion adjusted vs. $12.39 billion expected

Coke reported third-quarter net income attributable to shareholders of $3.7 billion, or 86 cents per share, up from $2.85 billion, or 66 cents per share, a year earlier.

Excluding restructuring charges and other items, Coke earned 82 cents per share.

Net sales rose 5% to $12.46 billion. Coke’s organic revenue, which strips out acquisitions, divestitures and foreign currency, increased 6%.

Shares climbed nearly 3% in premarket trading.

The company’s unit case volume rose 1%, a reversal from last quarter’s decline. The metric excludes the impact of pricing and foreign currency to reflect demand.

But volume in both Latin America and North America, two key markets, was flat for the quarter. Coke executives have previously said that low-income consumers in the U.S. have been buying fewer of its products, although the company is trying to target them with affordable options.

Worldwide, Coke saw the largest volume growth from its water, sports, coffee and tea segment. Its bottled water and sports drinks both saw volume increase 3%, while coffee and tea reported volume growth of 2%. The company’s sparkling soft drinks volume was flat for the quarter, while its juice, value-added dairy and plant-based beverage segment reported that volume shrank 3%.

The company reiterated its full-year forecast. Coke is expecting comparable earnings per share to rise 3% and organic revenue to increase 5% to 6%.

Looking ahead to 2026, Coke is projecting a slight tailwind to both its revenue and comparable earnings from currency fluctuations. The company will provide a full forecast for the upcoming year in its fourth-quarter earnings report.


Related Posts

Icotyde psoriasis pill from J&J to rival Tremfya Skyrizi IL-23 shots

Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg | Getty Images Johnson & Johnson on Wednesday said the U.S.…

Major League Baseball names Polymarket as prediction market partner

Shayne Coplan, chief executive officer of Polymarket, on the floor of the New York Stock Exchange (NYSE) in New York, US, on Thursday, Nov. 13, 2025. Michael Nagle | Bloomberg…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Cristiano Ronaldo’s 1000-goal chase is not an obsession, insists Portugal boss Roberto Martinez ahead of FIFA World Cup| Football News

  • By admin
  • March 22, 2026
  • 0 views
Cristiano Ronaldo’s 1000-goal chase is not an obsession, insists Portugal boss Roberto Martinez ahead of FIFA World Cup| Football News

Inside the 20,000-sq-ft Amritsar mansion that doubles as Ranveer Singh aka Hamza’s palatial bungalow in Dhurandhar 2 | Bollywood News

  • By admin
  • March 22, 2026
  • 0 views
Inside the 20,000-sq-ft Amritsar mansion that doubles as Ranveer Singh aka Hamza’s palatial bungalow in Dhurandhar 2 | Bollywood News

In a best-case scenario, the ongoing chaos can bring opportunity in next month, says expert

  • By admin
  • March 22, 2026
  • 0 views
In a best-case scenario, the ongoing chaos can bring opportunity in next month, says expert

What is Claude Code Channels, Anthropic’s take on OpenClaw-style AI agent setups? | Technology News

  • By admin
  • March 22, 2026
  • 0 views
What is Claude Code Channels, Anthropic’s take on OpenClaw-style AI agent setups? | Technology News

Mohsin Naqvi threatens legal action against international players choosing IPL 2026 over PSL: ‘2-3 have left’

  • By admin
  • March 22, 2026
  • 0 views
Mohsin Naqvi threatens legal action against international players choosing IPL 2026 over PSL: ‘2-3 have left’

Icotyde psoriasis pill from J&J to rival Tremfya Skyrizi IL-23 shots

  • By admin
  • March 22, 2026
  • 0 views
Icotyde psoriasis pill from J&J to rival Tremfya Skyrizi IL-23 shots